There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...
The likelihood for obstructive sleep apnea went down by 74% among adults with optimal vs. insufficient healthy lifestyle ...
From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
According to the Centers for Disease Control and Prevention, roughly one in three adults in the U.S. don’t get enough rest or sleep every day. Meanwhile, an estimated 50 million to 70 million people ...
According to the Hispanic Community Health Study, 14% of Hispanic men and 6% of Hispanic women have sleep apnea. With so many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback